Latest
19:14
17:24
【Fosun Pharma (02196.HK): DM1001 Preparation Obtains Clinical Trial Approval】NewTimeSpace News: Fosun Pharma announced on July 24 that its controlling subsidiary Fosun Wanbang received approval from the National Medical Products Administration (NMPA). The DM1001 preparation is authorized for clinical trials targeting signs and symptoms of idiopathic Parkinson's disease in adults, with Phase I clinical trials planned to be carried out in China once conditions permit.
Tag:
FOSUN PHARMA02196.HK
14:45